RBC Capital raised the firm’s price target on Pennant Group (PNTG) to $39 from $34 and keeps an Outperform rating on the shares. The Amedisys asset acquisition is likely underappreciated by the market, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PNTG: